- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Overcoming Immunotherapy Resistance: Identifying Non-Responders and Novel Approaches
The panel shares clinical practices for overcoming immunotherapy resistance in patients with non-small cell lung cancer.
EP: 1.Biomarker Testing and Guideline-Recommended Care in mNSCLC
EP: 2.Strategies to Increase Biomarker Testing Rates
EP: 3.Limitations on Optimal Biomarker Testing Rates
EP: 4.Impact of Biomarker Testing on Treatment Selection and Outcomes
EP: 5.Key Challenges and Unmet Needs in Newly Diagnosed Driver-Negative mNSCLC
EP: 6.NCCN Recommendations by PD-L1 Expression Level
EP: 7.Limitations of NCCN PD-L1 Expression Recommendations
EP: 8.Emerging Data and Evidence for Dual Immunotherapy plus Chemotherapy in First-Line mNSCLC
EP: 9.Genetic Alterations Impacting Treatment Response and Biomarker Testing Rates in mNSCLC
EP: 10.Molecular Characteristics Beyond Mutations Influencing Immunotherapy Response
EP: 11.Clinical Factors Impacting Immunotherapy Response and Optimizing Patient Selection
EP: 12.Overcoming Immunotherapy Resistance: Identifying Non-Responders and Novel Approaches
EP: 13.Key Takeaways on Enhancing Outcomes for mNSCLC Without Targetable Driver Mutations
Video content above is prompted by the following questions:
- What gaps remain in identifying likely non-responders to immunotherapy to guide alternative treatments?
- How does the toxicity profile of immuno-oncology regimens compare to standard chemotherapy options?
- Are there ongoing trials or research on novel combination approaches to overcome resistance and improve immunotherapy efficacy?
FDA Approves Companion Diagnostic for Tepotinib in MET Exon 14 mNSCLC
November 18th 2024The FDA approved the FoundationOne Liquid CDx to identify patients with metastatic non–small cell lung cancer (mNSCLC) with MET exon 14 skipping alterations who may be eligible for tepotinib (Tepmetko; EMD Serono).
Read More
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
Expanding Access to NSCLC Innovations: Challenges and Opportunities
October 18th 2024The current research focus for Umit Tapan, MD, Boston Medical Center, is reducing disparities in lung cancer care and improving treatment access, in particular for immunotherapy and targeted treatments.
Read More
